Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke.

Mair G, von Kummer R, Morris Z, von Heijne A, Bradey N, Cala L, Peeters A, Farrall AJ, Adami A, Potter G, Cohen G, Sandercock PA, Lindley RI, Wardlaw JM; IST-3 Collaborative Group.

Neurology. 2016 Jan 12;86(2):118-25. doi: 10.1212/WNL.0000000000002236. Epub 2015 Dec 9.

2.

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A.

Lancet. 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. Epub 2012 May 23. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

3.

Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited.

Sandercock P, Lindley R, Wardlaw J, Dennis M, Innes K, Cohen G, Whiteley W, Perry D, Soosay V, Buchanan D, Venables G, Czlonkowska A, Kobayashi A, Berge E, Slot KB, Murray V, Peeters A, Hankey GJ, Matz K, Brainin M, Ricci S, Cantisani TA, Gubitz G, Phillips SJ, Antonio A, Correia M, Lyrer P, Kane I, Lundstrom E; IST-3 collaborative group.

Trials. 2011 Nov 30;12:252. doi: 10.1186/1745-6215-12-252.

4.

Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.

Fung VS, Herawati L, Wan Y; Movement Disorder Society of Australia Clinical Research and Trials Group; QUEST-AP Study Group.

Mov Disord. 2009 Jan 15;24(1):25-31. doi: 10.1002/mds.21878.

PMID:
18846551
5.

Utility of a patient survey in identifying fluctuations in early stage Parkinson's disease.

Silburn PA, Mellick GD, Vieira BI, Danta G, Boyle RS, Herawati L.

J Clin Neurosci. 2008 Nov;15(11):1235-9. doi: 10.1016/j.jocn.2007.09.018. Epub 2008 Sep 27.

PMID:
18824360
6.

Predicting outcome in hyper-acute stroke: validation of a prognostic model in the Third International Stroke Trial (IST3).

SCOPE (Stroke Complications and Outcomes Prediction Engine) Collaborations; IST, Lewis SC, Sandercock PA, Dennis MS.

J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):397-400. Epub 2007 Aug 31.

PMID:
17766429
7.

Frequency doubling illusion VEPs and automated perimetry in multiple sclerosis.

Ruseckaite R, Maddess T, Danta G, James AC.

Doc Ophthalmol. 2006 Jul;113(1):29-41. Epub 2006 Aug 12.

PMID:
16906411
8.

Cerebrovascular disease associated with antiphospholipid antibodies: more questions than answers.

Hawkins C, Gatenby P, Tuck R, Danta G, Andrews C.

J Autoimmune Dis. 2006 Mar 30;3:3.

9.

Sparse multifocal stimuli for the detection of multiple sclerosis.

Ruseckaite R, Maddess T, Danta G, Lueck CJ, James AC.

Ann Neurol. 2005 Jun;57(6):904-13.

PMID:
15929047
10.

Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.

Beran RG, Berkovic SF, Black AB, Danta G, Hiersemenzel R, Schapel GJ, Vajda FJ.

Epilepsy Res. 2005 Jan;63(1):1-9. Epub 2005 Jan 6.

PMID:
15716083
11.

AUStralian study of titration to effect profile of safety (AUS-STEPS): high-dose gabapentin (neurontin) in partial seizures.

Beran R, Berkovic S, Black A, Danta G, Dunne J, Frasca J, Grainger K, Kilpatrick C, McKenzie R, McLaughlin D, Schapel G, Somerville E.

Epilepsia. 2001 Oct;42(10):1335-9.

12.

A novel syndrome of episodic muscle weakness maps to xp22.3.

Ryan MM, Taylor P, Donald JA, Ouvrier RA, Morgan G, Danta G, Buckley MF, North KN.

Am J Hum Genet. 1999 Oct;65(4):1104-13.

13.

Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy.

Beran RG, Berkovic SF, Dunagan FM, Vajda FJ, Danta G, Black AB, Mackenzie R.

Epilepsia. 1998 Dec;39(12):1329-33.

14.

A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures.

Beran RG, Berkovic SF, Buchanan N, Danta G, Mackenzie R, Schapel G, Sheean G, Vajda F.

Seizure. 1996 Dec;5(4):259-65.

PMID:
8952010
15.

Neurocysticercosis: an under-recognized cause of neurological problems.

Crimmins D, Collignon PJ, Dwyer D, Danta G.

Med J Aust. 1990 Apr 16;152(8):434-8.

PMID:
2329950
16.
17.
18.

Immunoglobulin deficient rats as donors and recipients of effector cells of allergic encephalomyelitis.

Willenborg DO, Sjollema P, Danta G.

J Neuroimmunol. 1986 Apr;11(2):93-103.

PMID:
2419359
19.

Immunoregulation of passively induced allergic encephalomyelitis.

Willenborg DO, Sjollema P, Danta G.

J Immunol. 1986 Mar 1;136(5):1676-9.

PMID:
2936807
20.

The fate of neonatally injected effector cells of allergic encephalomyelitis.

Willenborg DO, Sjollema P, Danta G.

Scand J Immunol. 1986 Jan;23(1):75-80.

PMID:
3486457

Supplemental Content

Loading ...
Support Center